Show simple item record

dc.contributor.authorKrakstad, Camillaen_US
dc.contributor.authorBirkeland, Evenen_US
dc.contributor.authorSeidel, Danilaen_US
dc.contributor.authorKusonmano, Kanthidaen_US
dc.contributor.authorPetersen, Kjellen_US
dc.contributor.authorMjøs, Siven_US
dc.contributor.authorHøivik, Erling Andreen_US
dc.contributor.authorWik, Elisabethen_US
dc.contributor.authorHalle, Mari Kyllesøen_US
dc.contributor.authorØyan, Anne Margreteen_US
dc.contributor.authorKalland, Karl-Henningen_US
dc.contributor.authorWerner, Henrica Maria Johannaen_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorSalvesen, Helga Birgitteen_US
dc.PublishedPLoS ONE 7(12): e52795eng
dc.description.abstractBackground: Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying molecular characteristics of primary and metastatic disease must be explored. Methodology/Principal Findings: We utilized the mass spectrometric-based mutation detection technology OncoMap to define the types and frequency of point somatic mutations in endometrial cancer. 67 primary tumors, 15 metastases corresponding to 7 of the included primary tumors and 11 endometrial cancer cell lines were screened for point mutations in 28 known oncogenes. We found that 27 (40.3%) of 67 primary tumors harbored one or more mutations with no increase in metastatic lesions. FGFR2, KRAS and PIK3CA were consistently the most frequently mutated genes in primary tumors, metastatic lesions and cell lines. Conclusions/Significance: Our results emphasize the potential for targeting FGFR2, KRAS and PIK3CA mutations in endometrial cancer for development of novel therapeutic strategies.en_US
dc.publisherPublic Library of Scienceeng
dc.relation.ispartof<a href="" target="blank">Mutations and gene amplifications in Endometrial Carcinomas. “Clinical characteristics and potential targets for therapy related to KRAS, MYC, ATAD2, PIK3CA and FGFR2 alterations”</a>eng
dc.rightsAttribution CC BYeng
dc.titleHigh-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutateden_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2012 Krakstad et al.

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY